Protein expression analysis of ALCAM and CEACAM6 in breast cancer metastases reveals significantly increased ALCAM expression in metastases of the skin

Journal of Clinical Pathology

Volumn 64, Issue 2, 2011, Pages 146-152

  Ihnen, Maike ^a   Kilic, Ergin ^b   Köhler, Nadine ^a   Löning, Thomas ^c   Witzel, Isabell ^a   Hagel, Christian ^a   Höller, Sylvia ^b   Kersten, Jan F ^a   Müller, Volkmar ^a   Jänicke, Fritz ^a   Milde Langosch, Karin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c ALBERTINEN KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6;

ADULT; AGED; ARTICLE; BONE CANCER; BRAIN CANCER; BREAST METASTASIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LUNG CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SKIN CANCER; SKIN METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL ADHESION MOLECULES, NEURONAL; FEMALE; FETAL PROTEINS; GPI-LINKED PROTEINS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM PROTEINS; SKIN NEOPLASMS;

EID: 79251491737     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.082602     Document Type: Article

References (35)

1. Landemaine T, Jackson A, Bellahcene A, et al. A six-gene signature predicting breast cancer lung metastasis. Cancer Res 2008;68:6092-9.
2. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49. (Pubitemid 36808649)
3. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
4. Minn AJ, Kang Y, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumours. J Clin Invest 2005;115:44-55. (Pubitemid 40385504)
5. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008;68:3108-14.
6. Paschos KA, Canovas D, Bird NC. The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal 2009;21:665-74.
7. Schmidmaier R, Baumann P. ANTI-ADHESION evolves to a promising therapeutic concept in oncology. Curr Med Chem 2008;15:978-90. (Pubitemid 351736400)
8. Gout S, Tremblay PL, Huot J. Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis. Clin Exp Metastasis 2008;25:335-44. (Pubitemid 351752950)
9. King J, Ofori-Acquah S, Stevens T, et al. Potential role for activated leukocyte cell adhesion molecule and neural cadherin in metastasis to the lung microcirculation. Chest 2004;125:150S-1.
10. van Kempen LC, Nelissen JM, Degen WG, et al. Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem 2001;276:25783-90.
11. Kristiansen G, Pilarsky C, Wissmann C, et al. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 2003;54:34-43.
12. Lunter PC, van Kilsdonk JW, van Beek H, et al. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res 2005;65:8801-8.
13. van Kempen LC, van den Oord JJ, van Muijen GN, et al. Activated leukocyte cell adhesion molecule/CD166, a marker of tumour progression in primary malignant melanoma of the skin. Am J Pathol 2000;156:769-74.
14. Verma A, Shukla NK, Deo SV, et al. MEMD/ALCAM: a potential marker for tumour invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology 2005;68:462-70. (Pubitemid 41160978)
15. Weichert W, Knosel T, Bellach J, et al. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004;57:1160-4. (Pubitemid 39486521)
16. Burkhardt M, Mayordomo E, Winzer KJ, et al. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol 2006;59:403-9.
17. Ihnen M, Muller V, Wirtz RM, et al. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 2008;112:419-27.
18. King JA, Ofori-Acquah SF, Stevens T, et al. Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 2004;6:R478-87.
19. Blumenthal RD, Leon E, Hansen HJ, et al. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer 2007;7:2.
20. Duxbury MS, Ito H, Benoit E, et al. A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res 2004;64:3987-93.
21. Maraqa L, Cummings M, Peter MB, et al. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. Clin Cancer Res 2008;14:405-11.
22. Mezzanzanica D, Fabbi M, Bagnoli M, et al. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 2008;14:1726-33.
23. Blumenthal RD, Hansen HJ, Goldenberg DM. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res 2005;65:8809-17.
24. Riley CJ, Engelhardt KP, Saldanha JW, et al. Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res 2009;69:1933-40.
25. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002;41:154-61.
26. Remmele W, Stegner H. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-40.
27. R Development Core Team RFfSC. R: A language and environment for statistical computing. 2009. Vienna, Austria. ISBN 3-900051-07-0. http://www.R-project.org.
28. Ihnen M, Kohler N, Kersten JF, et al. Expression levels of Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) in primary breast carcinoma and distant breast cancer metastases. Dis Markers 2010;28:71-8.
29. Degen WG, van Kempen LC, Gijzen EG, et al. MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol 1998;152:805-13.
30. Davies SR, Dent C, Watkins G, et al. Expression of the cell to cell adhesion molecule, ALCAM, in breast cancer patients and the potential link with skeletal metastasis. Oncol Rep 2008;19:555-61.
31. Choi S, Kobayashi M, Wang J, et al. Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumour cells after chemotherapy with Adriamycin. Clin Exp Metastasis 2000;18:45-50.
32. Smid M, Wang Y, Klijn JG, et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006;24:2261-7. (Pubitemid 46630655)
33. Lewis-Wambi JS, Cunliffe HE, Kim HR, et al. Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells. Eur J Cancer 2008;44:1770-9.
34. Strickland LA, Ross J, Williams S, et al. Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol 2009;218:380-90.
35. Wiiger MT, Gehrken HB, Fodstad Ø, et al. A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth. Cancer Immunol Immunother 2010;59:1665-74.